Sanofi’s blood cancer treatment has achieved key co-primary endpoints in the phase 3 Iraklia study. The stock gained 1% today in Paris, continuing its newly found upward trend after a dismal slide in late 2024.
According to the press release, the new subcutaneous (SC) formulation of Sarclisa, combined with pomalidomide and dexamethasone, demonstrated a non-inferior objective response rate when delivered via an on-body delivery system (OBDS), compared to the traditional intravenous weight-based dose of Sarclisa. The treatment also met secondary endpoints, including a ‘very good’ partial response rate and reduced infusion reactions.
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appThe SC formulation, administered through the hands-free, automated enFuse OBDS, offers patients a more convenient and time-efficient treatment option, reflecting Sanofi’s patient-centered strategy. The company plans to seek regulatory approval for the SC formulation of Sarclisa in both the US and EU in the first half of 2025.
2024 performence and 2025 outlook
Sanofi’s stock has been on a rather challenging ride in 2024. By beating EPS estimated over the first three quarters of the previous year, the company set itself on an upward ride, additionally supported by favorable analysts’ ratings. One of the key drivers of Sanofi’s success has been its blockbuster immunology drug Dupixent, with sales going up almost 24% in Q3 and confirmed full-year 2024 target of €13 bn.
The overall sentiment in the drug and biotech sector weakened in the final quarter of 2024, driven by guidance cuts, pipeline setbacks, and concerns over the political environment, including the appointment of R.F. Kennedy as Head of the Health and Human Services Department. Despite tight competition and an uncertain regulatory outlook under Trump’s administration, investors are far from pessimism. Sanofi's robust project portfolio (including 5 projects in registration and 27 in phase 3 trials, including 3 vaccines) positions the company well for a potential stock rebound, given that successive administrative approvals are secured.
Sanofi's US-quoted stock (SNY.US) has recently broken above the shorter-term 30-period Exponential Moving Average (light purple) and is now trading above the 23.6% Fibonacci retracement level. The rebound from the well-tested support near $46, combined with recent price action, indicates a potential trend reversal heading into 2025.
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
